Lupus & antiphospholipid syndrome
Dual‐Targeting BCMA – CD19 CAR ‐T Cell Therapy in Systemic Lupus Erythematosus: Single‐Cell and Immune Repertoire Analysis Reveals Mechanisms of Immune Reconstitution
Authors' conclusion
BCMA-CD19 dual CAR-T therapy was associated with deeper depletion of plasma-lineage compartments and a tendency toward more pronounced reversal of SLE-associated molecular signatures.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE) receiving CAR-T therapy; peripheral blood mononuclear cells176,182 single cells analysed
- Participants
- 15 patients
- Comparison
- BCMA-CD19 dual-targeting CAR-T vs CD19 single-targeting CAR-T (public datasets) and healthy controls
- Dual-targeting CAR-Tn = 5
- CD19 single-targeting CAR-Tn = 7reference
- Healthy controlsn = 3
- Outcome
- Changes after dual-targeting CAR-T
- Follow-up
- Median 90 days postinfusion
Methodological detailssingle-cell RNA sequencing, B cell receptor (BCR) and T cell receptor sequencing, integrated with public datasets
- Single-cell RNA sequencing
- BCR and T cell receptor sequencing
- Integrated with public datasets
Main finding
As reported in the abstract
- BCR repertoire shift toward IGHM-dominant (49.83%-89.19%), naïve-biased profile
- P < 0.05
Further findings
Mean SLEDAI, dual-targeting cohort
- Mean SLEDAI decreased from 9.6 to 2.4
- P < 0.05
Original publication
Dual‐Targeting BCMA – CD19 CAR ‐T Cell Therapy in Systemic Lupus Erythematosus: Single‐Cell and Immune Repertoire Analysis Reveals Mechanisms of Immune Reconstitution. Arthritis Rheumatol. Published 2 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →